1. Cantonal R&D Tax Incentives (TRAF Framework)
Switzerland’s corporate tax incentives for research and development are largely implemented at cantonal and communal level following the Tax Reform and AHV Financing (TRAF) reforms introduced in 2020. No specific R&D tax incentives are available at federal level.
R&D super deduction
Most cantons offer an additional tax deduction for qualifying R&D expenditure carried out in Switzerland. Under this super deduction mechanism, companies may deduct more than 100% of eligible R&D costs from their taxable income.
The level of uplift varies by canton but typically allows an additional deduction of up to 50% of qualifying R&D expenses. In practice, this can result in an effective deduction of up to 140% of eligible costs in certain cantons.
Eligible expenditure generally includes:
- Personnel costs directly attributable to R&D activities conducted in Switzerland.
- A notional uplift, often around 35%, to cover ancillary R&D overheads.
- Up to 80% of costs incurred for contract R&D performed by third parties within Switzerland.
Patent box regime
Cantons may also apply a patent box regime that reduces the tax burden on income derived from qualifying intellectual property. Up to 90% of net profits attributable to qualifying patents and comparable rights, including Swiss, European and foreign patents as well as supplementary protection certificates, may be exempt from cantonal and communal taxation.
This regime significantly lowers the effective tax rate on patent-related income and encourages companies to locate IP ownership, development and commercialisation activities in Switzerland.
Tax holidays and negotiated relief
Many cantons offer tax holidays or substantial tax relief for newly established companies or for significant expansion investments. These incentives are typically granted for periods of up to ten years and are often negotiated in the context of regional economic development objectives. In specific cases, relief may also extend to elements of federal taxation.
Collectively, these cantonal incentives make Switzerland highly competitive for R&D-intensive businesses, particularly in sectors such as pharmaceuticals, biotechnology, medtech and advanced manufacturing.
2. Innosuisse Grants
Innosuisse, the Swiss Innovation Agency, is the principal source of direct, non-dilutive public funding for innovation. It supports science-based innovation across the full spectrum from start-ups to established companies collaborating with research institutions.
Start-up innovation projects.
Innosuisse provides direct funding to science-based start-ups, typically less than five years old and employing fewer than 50 full-time equivalents. These projects focus on pre-market innovation with scalable commercial potential.
Innosuisse generally funds up to 70% of eligible direct project costs, including personnel, materials and external services, with the beneficiary company co-funding the remaining portion.
Innovation projects with implementation partners
Innosuisse also supports collaborative projects where a company works with a Swiss research partner such as a university or public research institution. These projects are designed to translate applied research into market-ready solutions, with public funding typically covering the research partner’s costs.
BRIDGE and international programmes
Through the BRIDGE programme, jointly operated with the Swiss National Science Foundation, Innosuisse supports projects that bridge the gap between academic research and commercial application. In addition, Innosuisse funds Swiss participants in international programmes such as Horizon Europe, Eurostars and the EUREKA network, ensuring continued international integration of the Swiss innovation ecosystem.
3. Swiss National Science Foundation
The Swiss National Science Foundation is the primary public funder of basic and application-oriented scientific research in Switzerland. It provides competitive grants to researchers at universities and research institutions across all disciplines.
Funding is typically awarded through multi-year project grants and career-focused schemes, ensuring a strong pipeline of high-quality research. Although SNSF funding is not directly targeted at commercialisation, it forms the foundational knowledge base that feeds into applied innovation, start-up creation and industry collaboration supported by Innosuisse.
4. Venture Capital and Private Innovation Support
Switzerland has a mature and active venture capital ecosystem, particularly strong in life sciences, health technology, deep tech and fintech. The country consistently ranks among global leaders for venture capital investment on a per-capita basis.
Despite this strength, structural challenges remain. The legal and tax framework for establishing domestic venture capital funds can be restrictive, leading some fund managers to domicile vehicles abroad. This has, at times, created funding gaps for larger later-stage investments within Switzerland.
Private and philanthropic initiatives play a crucial role in addressing early-stage financing needs. Venture Kick is a prominent example, providing staged seed funding of up to CHF 150,000 to academic spin-offs, alongside access to private investors through affiliated funds.
Universities and cantons also provide targeted support. Institutions such as ETH Zurich and EPFL operate dedicated grant, fellowship and incubator programmes, including ETH Pioneer Fellowships and EPFL Innogrants, often in close cooperation with cantonal development agencies and innovation hubs.
Conclusion
Switzerland’s innovation funding framework combines decentralised but powerful cantonal tax incentives with substantial non-dilutive federal grant support and a dynamic private investment landscape. The interaction between R&D super deductions, patent box regimes, Innosuisse grants and strong academic research funding creates a coherent and highly effective environment for innovation.
This balanced approach enables Switzerland to retain high-value research, attract global talent and capital, and support the full innovation lifecycle from fundamental research through to global commercialisation, reinforcing its position as a leading global innovation hub.
We’re here to help. Contact us to discuss how ABGi can support your global innovation strategy.
